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Tick-borne encephalitis virus (TBEV) is the aetiological agent of tick-borne encephalitis (TBE), a 
potentially fatal central nervous system infection of humans. TBE is endemic in many areas of Europe 
and Asia; however, very scarce data on TBEV activity are available from Turkey. We aimed to identify 
TBEV exposure in healthy blood donors and the impact of TBEV in central nervous system infections 
in Central/Northern Anatolia. Two-thousand four hundred and fifty four sera, collected from blood 
donors at Ankara, Konya, Eskişehir and Zonguldak branches of the Turkish Red Crescent Middle 
Anatolia Regional Blood Center, were analysed for TBEV serosurveillance. Paired serum and 
cerebrospinal fluid samples from 108 patients with the diagnosis of aseptic meningitis/encephalitis of 
unknown aetiology were also evaluated to identify TBE and neuroborreliosis cases. Commercial 
enzyme-linked immunosorbent assays and indirect immunofluorescence tests were employed for 
antibody detection. Forty-seven donor samples (1.9%) were reactive for TBEV IgG. In 25 persons with 
IgG reactivity (53.1%), risk factors for tick-borne infections were revealed. One sample from Zonguldak 
province (1/198; 0.5%) in the Black Sea region of Turkey was confirmed to possess neutralizing 
antibodies via plaque reduction neutralization test. TBEV IgM was detected in 7.4% (8/108) of the 
patients. IgM was accompanied by IgG reactivity in two persons where, in one, recent history of a tick 
bite was also identified. Intrathecal antibody production for TBEV could not be demonstrated. No 
evidence for Borrelia infections could be found. Confirmed exposure to TBEV and/or an antigenically 
similar tick-borne flavivirus is documented for the first time in blood donors in Zonguldak in Northern 
Anatolia. Probable cases of TBE have also been identified from Central Anatolia. The epidemiology of 
TBEV activity in Turkey needs to be assessed and benefits of vaccination for general population, risk 





Tick-borne encephalitis virus (TBEV), an enveloped, positive-strand RNA virus classified in 
Flaviviridae, is the aetiological agent of tick-borne encephalitis (TBE), a potentially fatal central 
nervous system (CNS) infection of humans (Monath, 1990). The virus, transmitted mainly by Ixodid 
ticks, is endemic in many areas of Europe and Asia (Suss, 2003). A significant increase has been 
noted for TBE morbidity from 1974 to 2003 and the virus is currently detected in previously unaffected 
regions (Randolph, 2002; Broker and Gniel, 2003; Suss, 2003; Mansfield et al., 2009). A very efficient 
vaccine, which has been implemented in vaccination programmes in various countries and has 
successfully decreased the morbidity associated with the infection, is available to prevent TBE (Kunz, 
2003; Mansfield et al., 2009). The information on TBEV activity in Turkey, which shares certain 
climatic and ecological conditions with the endemic zones, is limited (Suss, 2008). The initial evidence 
of TBEV-related infections in Turkey dates back to 1968, when three patients with 
meningoencephalitis had been retrospectively diagnosed as TBE via rises in the haemagglutination 
inhibiting antibody titres (Serter, 1968). Plaque reduction neutralization test (PRNT)-confirmed 
seroprevalence rates of 1.21% and 1.29% were reported from 1074 humans and 155 sheep from 
Aegean (western Anatolia) and Mediterranean (southern Anatolia) regions of Turkey in 1980 and 1971 
respectively (Radda, 1971; Serter, 1980). Recently, TBEV reactive IgGs have been detected by 
enzyme-linked immunosorbent assay (ELISA) in 1.4% of 274 persons with the history of tick bites and 
in 7 of 39 persons under investigation for Crimean Congo Hemorrhaggic Fever from Central/Northern 
Anatolia, where a probable case with IgM reactivity has also been announced (Uyar et al., 2007; Esen 
et al., 2008). We have documented the evidence for possible TBEV infections in Southeastern Turkey 
  
(Ergunay et al., 2007). However, these recent studies cover only relatively small groups and the 
serological assay results have not been confirmed and thus viral activity in the region could not be 
firmly established. Therefore, we aimed to identify TBEV exposure in healthy blood donors from 
Central/Northern Anatolia where no previous seroprevalence data are available and the role of TBEV 
in CNS infections from Central Anatolia.  
 
 
Materials and Methods 
 
Sera from blood donors 
A total of 2454 sera, collected from volunteer blood donors after informed consent between January 
and April 2009 at four major branches (Ankara, Konya, Eskişehir and Zonguldak provinces, Table 1) 
affiliated with the Turkish Red Crescent Middle Anatolia Regional Blood Center, were included. The 
distribution of sera was determined according to the population density of each region (Fig. 1). Donor 
sampling was performed at all branches and by permanent and mobile donation units covering all 
regions of the particular province. Ankara is the capital and second most densely populated city in 
Turkey. Mean age of the study groups from each region were Ankara: 32.51 years (range: 18–64, 
standard deviation: 13.51), Konya: 34.84 (range: 20–62, standard deviation: 14.02), Eskisehir: 38.43 
(range: 19–61, standard deviation: 13.76) and Zonguldak: 30.22 (range: 19–59, standard deviation: 
12.89). All participants filled out a survey questionnaire to identify various risk factors for vector-borne 
infections and Flavivirus vaccinations. All sera were transported on dry ice and stored in aliquots in )20 
and )80°C.  
 
 
Serum-cerebrospinal fluid samples from patients  
Paired serum and cerebrospinal fluid (CSF) samples obtained from 108 adult patients with the 
preliminary diagnosis of aseptic meningitis/encephalitis of presumed viral aetiology were evaluated 
retrospectively. The samples were stored in aliquots in )20 and )80°C for future analysis at the 
Hacettepe University Hospital Central Laboratory. They were collected between April and October 
2009 and cultures for Mycobacterium tuberculosis and other causes of bacterial meningitis, as well as 
polymerase chain reaction (PCR) assays for Herpes viruses, were negative. Clinical history and 
laboratory data of the patients were retrieved from medical records.  
 
The study was performed after approval from Hacettepe University Medical Ethics Committee, in 
compliance with the World Medical Association Declaration of Helsinki and according to the blood 
donation official guidelines of Turkish Red Crescent Society as approved by Turkish Ministry of Health. 
 
 
Blood donor surveillance 
Sera from blood donors were analysed quantitatively for TBEV IgG by a commercial ELISA (Anti-TBE 
Virus IgG ELISA; Euroimmun, Lubeck, Germany) according to the manufacturer’s instructions. Test 
results were expressed in relative units per millilitre (RU/ml), calculated according to the standard 
curve formed by including three calibrator sera with known antibody titres at each run. Samples with 
antibody levels of ‡20 RU/ml were considered positive and 10–19 RU/ml were considered borderline. 
Samples with positive/borderline TBEV IgG ELISA results were further tested with a commercial TBEV 




TBEV plaque reduction neutralization test  
Sera from blood donors that were positive/borderline for TBEV IgG were tested for neutralizing 
antibodies by PRNT to confirm specificity. Initially, PS cells (5 x 105 cells/ml; 300 ll) were seeded in a 
24-well plate. The sera and the controls were mixed 1 : 5 with L15 medium, incubated for 30 min at 
56°C and 2-fold dilution series (1 : 5 to 1 : 160) were prepared. A dilution of 1.67 x 102 PFU/mL of the 
TBE strain K23 was prepared and each serum dilution was mixed with an equal amount of virus (250 
ll), resulting in final dilutions of 1 : 10 to 1 : 320. For the virus control, the virus was mixed 1 : 2 with 
L15 medium. All dilutions were incubated for 30 min at 37°C and 200 ll was then added to the seeded 
cells. The plates were incubated for 4 h at 37°C, overlaid with 1.6% carboxymethyl cellulose in L15 
medium and incubated for 4 days at 37°C. The cells were fixed for 30 min with 3.7% formaldehyde, 
stained with naphthalene-black for another 30 min and the plate was washed with water and dried. 
The plaques were counted and the 90% plaque reducing neutralization titre (NT90) was calculated as 
described previously (Hierholzer and Killington, 1996)  
  
Screening of sera–CSF pairs from patients  
Samples from aseptic meningitis/encephalitis patients were tested for TBEV and Borrelia IgG/IgM via 
commercial indirect immunofluorescence tests (IIFTs) and ELISAs according to the manufacturer’s 
instructions respectively (Anti-TBE Virus IgM/IgG IIFT, Anti-TBE Virus IgM/IgG ELISA, Anti-
Borrelia+VlsE IgM/IgG ELISA; Euroimmun). Borrelia IgG/IgM positive results in sera were further 
tested via Anti-Borrelia EUROLINERN-AT (Euroimmun) for confirmation.  
 
 
Evaluation of TBEV positive sera–CSF samples  
Samples with positive for TBEV IgM/IgG results were evaluated by commercial IIFT and ELISA tests 
(Anti-West Nile virus IgM/IgG IIFT, Anti-West Nile virus IgM/IgG ELISA, Anti-Measles virus IgG ELISA; 
Euroimmun) to identify cross-reactions and/or other causes of CNS infections. Intrathecal antibody 
production for TBEV, Borrelia and Measles virus was determined for positive samples with specific 
commercial ELISA tests (Anti-TBE Virus ELISA IgM/IgG in CSF, Anti-Borrelia+VlsE IgM/IgG ELISA in 
CSF, Anti-Measles Virus IgG in CSF; Euroimmun). All assays were performed and evaluated 
according to the manufacturer’s instructions. Samples reactive for West Nile Virus IgM were further 





TBEV seroprevalence in blood donors 
A total of 47 samples (47/2454; 1.9%) yielded positive/borderline results for TBEV IgG by ELISA. In 25 
persons with IgG reactivity (25/47; 53.1%), risk factors for tick-borne infections (tick exposure, 
consumption of unpasteurized milk, outdoor working /tracking /residing in forests or tick-infested 
areas) were identified. None of these donors had a history of TBE/Yellow Fever/Japanese Encephalitis 
vaccination or travelling to TBE-endemic regions. All samples were negative for TBEV IgM.  
 
Plaque reduction neutralization test identified only one sample (1/47; 2.1%) to possess neutralizing 
antibodies for TBEV (NT90:17). The confirmed sample was obtained from a 27-year-old male donor 
residing in Kilimli neighbourhood of Zonguldak province, Black Sea region of Turkey. At the time of 
donation, he was employed as a construction worker and had outdoor activities in the forest /tick-
infested areas, but had not recalled a tick-bite or had no means of contact with sheep. The distribution 
of ELISA/PRNT results according to the site of blood donation is given in Table 1.  
 
 
TBEV/Borrelia detection in patients 
Tick-borne encephalitis virus IgM was identified by ELISA in seven, by IIFT in two serum samples 
(total: 9/ 108; 8.3%). Sera with IgM positivity via IIFT (n: 2) were accompanied by a borderline IgM 
ELISA and a positive IgG IIFT result respectively. In an ELISA IgM positive sample, IgG was also 
positive by IIFT+ELISA, thus, a total number of two samples (2/108; 1.8%) have been found reactive 
for IgM+IgG by various assays (Table. 2). One sample with TBEV IgG reactivity only was also 
revealed by ELISA+IIFT. Intrathecal synthesis and presence of antibodies in CSF could not be 
demonstrated for any of the corresponding serum IgM/IgG reactive samples.  
 
Three serum samples with TBEV IgM reactivity were borderline for West Nile Virus IgM by ELISA or 
IIFT (Cases 2, 3 and 7; Table 2). These were evaluated for West Nile Virus RNA and found to be 
negative. In two samples reactive for TBEV IgM and measles virus IgGs, specific antibody production 
against measles virus was identified in CNS and these were excluded from the review for the 
presumed TBE cases.  
 
Anti-Borrelia IgM and IgGs were detected in 14 (14/ 108; 12.9%) and 8 (8/108; 7.4%) sera by ELISA 
respectively, where one sample was positive for both IgM and IgG. None of the samples could be 
confirmed by the commercial line blot assay utilizing native and recombinant Borrelia antigens and no 
intrathecal antibody production was identified.  
 
Patient history, clinical laboratory data could be retrieved and reviewed in six of eight TBEV IgM 
positive individuals and only laboratory test results were available for two cases. All persons had fever 
(>37.8°C) and normal liver function tests at the time of presentation. Clinical and laboratory data of 






Tick-borne encephalitis is an emerging disease and the most important flavivirus infection of the CNS 
in Europe and Russia (Pugleise et al., 2007). TBE incidence has been observed to increase in both 
high and low risk areas in certain endemic countries and new TBE foci have appeared possibly due to 
complex interactions among climatic, social and ecological factors (Haglund, 2002; Randolph, 2002; 
Sumilo et al., 2008). Very scarce data on neutralization-confirmed TBEV activity are currently available 
from Turkey (Radda, 1971; Serter, 1980). This study was designed to reveal virus exposure in healthy 
blood donors and the impact of TBEV in cases of aseptic meningitis/encephalitis of unknown 
aetiology, retrospectively screened to identify TBE-induced syndromes. TBEV IgG/IgMs were 
determined via commercial ELISA/IIFTs with enhanced specificity/sensitivity and seroprevalence 
results were confirmed by PRNT. To our knowledge, this is the largest study investigating human TBE 
exposure from Turkey and the first to reveal TBE activity in Central/ Northern Anatolia.  
 
The only human seroprevalence data on TBEV come from Aegean region (western border) of Turkey 
where antibodies were detected by haemagglutination inhibition (HI) assay and were confirmed by 
neutralization in 13 of 1074 residents (1.21%) of Izmir province (Serter, 1980). Evidence for viral 
activity in Mediterranean region (southern Turkey) had also been provided, by detecting TBEV 
neutralizing antibodies in 1.29% (2/155) of sheep in Hatay province (Radda, 1971). Although not 
confirmed, TBE IgG has also been detected by ELISA in 1.1% (3/274) persons with a history of tick 
bite from Central Anatolia, raising the possibility of viral activity in this region (Uyar et al., 2007). In this 
study, we have investigated TBEV exposure in blood donors at four major branches (in Ankara, 
Konya, Eskisehir and Zonguldak provinces) of Turkish Red Crescent Middle Anatolia Regional Blood 
Center, covering a relatively large sampling zone in central and northwestern Anatolia. Although 
ELISA reactive samples have been detected at a rate of 1.83% (45/2454), no confirmed exposure has 
been identified from Ankara, Konya, Eskisehir regions (Table 1). One of the two ELISA positive 
samples from Zonguldak in the Black Sea region has been reactive in PRNT, providing the only 
confirmed TBEV IgG in our study, and indicates virus activity in the northwestern part of Turkey (Table 
1). The exposed person, although not recalling any tick bites, had stated to have outdoor activities in 
the forest/tick-infested areas. Black Sea region is an established habitat for Ixodid ticks; the ecological 
and climatic conditions of the region generally favour tick activity (Aydin and Bakirci, 2007).  
 
Ixodes ricinus ticks have been widely recognized as the major vector for European TBEV subtype and 
Ixodes persulcatus is mainly responsible for transmitting Siberian/ Far Eastern TBEV subtypes 
(Charrel et al., 2004). It is generally accepted that other Ixodid species such as Ixodes hexagonus and 
certain Haemaphysalis/Dermacentor species are competent as vectors and may transmit the virus 
(Suss, 2003). Turkey’s tick fauna has been shown to include about 32 species and Ixodes spp. have 
been detected mostly in Northern Turkey, where the amount of rainfall during the year is the highest 
and intensive forests are the predominant vegetation (Aydin and Bakirci, 2007). Nevertheless, in 
addition to the Black Sea region, I. ricinus activity has been shown to be present in Mediterranean, 
Aegean and east/southeast Anatolia (Aydin and Bakirci, 2007). TBEV has not yet been detected in 
ticks in Turkey and the vector species for TBEV transmission is, therefore, not validated. The 
consumption of unpasteurized goat or cow milk, which is widely practised especially in rural areas in 
Turkey, is also verified as an alternative route for TBEV infection (Monath, 1990) and therefore may be 
acting as a potential means of transmission. The probable impact of this practice is also reflected in 
our blood donor risk assessment survey where in 25 TBEV IgG positive/borderline donors with risks 
for tick-borne diseases, eight persons (32%) have stated their frequent use of unpasteurized milk/milk 
products (data not shown).  
 
In retrospective screening of serum and CSF samples from 108 patients with aseptic 
meningitis/encephalitis of unknown aetiology, we have identified TBEV serum IgM reactivity in eight 
patients (7.4%), accompanied by IgG in two of the eight sera. No reactivity in CSF antibody assays 
was observed. Assays to detect viral RNA have not been performed due to lack of sufficient amounts 
of samples and as viral nucleic acid/antigen detection is unsuccessful in the majority of the 
neurological phase of the infection after the immune response have been mounted (Holzmann, 2003). 
As the study was conducted by using previously stored samples, investigation of the cases was 
confined to the medical records, and convalescent serum samples were not available for confirmation. 
As TBE vaccines have been neither registered nor used in Turkey, and no record of any other 
Flaviviral vaccination or travelling to endemic regions was available, the TBEV IgM seroreactivity 
observed in the patients is very likely to indicate exposure to TBE and strongly associated with the 
documented CNS infections. The identification of the history of a recent tick bite and presence of a 
non-specific febrile disease preceding the initiation of CNS symptoms as well as IgG reactivity further 
  
supported the diagnosis in certain cases (Table 2) (Holzmann,2003). It is generally accepted that 
detection of IgG and/or IgM in serum in a clinically compatible case warrants the diagnosis of probable 
or confirmed TBE case (Holzmann, 2003; Gunther and Lindquist, 2005; Stefanoff et al., 2005). 
Detection of TBEV IgM is also said to be sufficient for cases with presentations 
in routine clinical practice in endemic regions (Gunther and Lindquist, 2005). These definitions are 
harder to comprehend for Turkey due to the paucity of published TBE reports, and virus epidemiology 
being not completely understood. Nevertheless, it is evident that for at least two cases in the study 
group, all case definition requirements were fulfilled and the diagnosis is further supported by the 
medical history as well as laboratory results (Table 2).  
 
Co-infections of TBEV and Borrelia have been shown to occur and have already been revealed in 
several countries in Europe (Korenberg, 2004). It is suggested that in cases with TBE-related CNS 
disease, infection with Borrelia should also be considered (Cimperman et al., 1998). Although we have 
identified Borrelia antibodies in 21 individuals (21/108; 19.4%), none could be confirmed and 
intrathecal antibodies have not been identified; thus, neuroborreliosis was ruled out in the study group. 
In three patients with TBEV IgM reactivity, borderline results for West Nile Virus IgM have been 
observed, but viral RNA could not be detected. West Nile Virus has been documented previously to 
circulate in Central Anatolia (Ergunay et al., 2009) and may also cause CNS symptoms and 
serological cross-reactivity (Monath, 1990; Allwinn et al., 2002).  
 
The first TBE case report from Aegean region, Turkey was published locally in 1968, where significant 
increase in TBEV antibody titres in the HI assay was detected in three patients with CNS infections 
from the Aegean region. All persons had presented predominantly with meningeal symptoms and had 
recovered without sequelae (Serter, 1968). We have also identified TBEV IgM+IgG reactivity in six 
persons from southeastern Turkey, but the diagnosis of TBE could not be suggested due to the lack of 
relevant clinical data (Ergunay et al., 2007). Esen et al. (2008) identified a probable case with only IgM 
positivity in Tokat province in the Black Sea region with a history of tick bite which had an 
unfavourable clinical course, resulting in mortality. The clinical presentation and progression observed 
for the probable TBE cases identified in our study are generally mild, and meningitic/ meningomyelitic 
symptoms predominate (Table 2). Majority of the patients (7/8) had recovered without sequelae, 
whereas in one case, muscle paresis had persisted on discharge from the hospital. Thus, it can be 
suggested that the clinical course of the suspected TBE cases was similar to TBE observed with 
European subtype of the virus (Gritsun et al.,2003; Haglund and Gunther, 2003).  
 
An acute form of encephalomyelitis was recognized in sheep in the Gebze area of northwestern 
Turkey in the 1960s and the causative virus, called Turkish Tick-borne Encephalitis or Turkish sheep 
encephalitis virus (TSEV), was identified (Hartley et al.,1969; Grard et al., 2007). TSEV, initially 
considered as a subtype of Louping ill virus (LIV), is shown to be genetically more closely related to 
the tick-borne encephalitis complex viruses (especially the European subtype of TBEV) than to LIV, 
but despite common biological properties, TSEV is considered a subtype neither of LIV nor of TBEV 
(Whitby et al., 1993; Grard et al., 2007). The epidemiology of TSEV in Turkey has not been studied in 
humans, animals or tick vectors and no data relevant to the vertebrate exposure are available. TSEV 
has not yet been associated with CNS diseases in humans. Serological studies on the structural 
relationship of TSEV to other viruses of the TBE complex revealed that antigenic variation existed 
between TSEV and other TBE viruses (Hambleton et al., 1983; Stephenson et al., 1984). 
Nevertheless, cross-reactions in commercial serological tests as well as in PRNT cannot be entirely 
ruled out. More data on TSE are required to estimate the occurence/extent of human exposures as 
well as the impact on animal health in Turkey.  
 
Turkey, currently, is not an established TBE focus and awareness among physicians and diagnostic 
microbiologists is low; therefore, probable TBEV-related clinical conditions are likely to be overlooked. 
No established surveillance programmes related to tick epidemiology exist in Turkey, but studies by 
various groups have aided to reveal the vector ecology and epidemiology of ticks (Aydin and Bakirci, 
2007). Implementation of surveillance programmes and identification of high risk areas for animals and 
humans are needed for a better understanding of tick-borne diseases in Turkey.  
 
In conclusion, confirmed exposure to TBEV and/or an antigenically similar flavivirus is documented for 
the first time in healthy blood donors in Zonguldak in Northern Anatolia. Probable TBE-related cases of 
CNS infections have also been identified from Central Anatolia. The distribution of TBEV/TSEV activity 
in Turkey awaits assessment and benefits of TBE vaccination for 
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Tables and Figures 
 
 
Table 1 Distribution of samples according to the region of blood donation and TBEV antibody results 
by ELISA and PRNT 
 
TBEV, tick-borne encephalitis virus; ELISA, enzyme-linked immunosorbent assay; PRNT, plaque 









TBE, tick-borne encephalitis; ELISA, enzyme-linked immunosorbent assay; IIFT, indirect 
immunofluorescence test; CSF, cerebrospinal fluid; n.i., no information. 
* Vaccination against TBE, Yellow Fever, Japanese Encephalitis, travel to TBE and/or Dengue  
endemic areas. 
† Include alterations of consciousness, convulsions, muscle hyperkinesia, tremors and vertigo. 




Figure 1 Map showing the blood donor sampling regions in the study (see Materials and Methods for 
details). 
 
 
 
 
  
